Tejara Capital Ltd Takes $1.01 Million Position in uniQure N.V. $QURE

Tejara Capital Ltd acquired a new stake in uniQure N.V. (NASDAQ:QURE) in the fourth quarter, Holdings Channel reports. The firm acquired 42,000 shares of the biotechnology company’s stock, valued at approximately $1,005,000.

Several other large investors have also recently added to or reduced their stakes in the business. Jones Financial Companies Lllp lifted its holdings in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure in the third quarter worth $50,000. Torren Management LLC purchased a new stake in shares of uniQure during the fourth quarter worth $28,000. FNY Investment Advisers LLC increased its position in shares of uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 718 shares during the period. Finally, Knott David M Jr acquired a new stake in shares of uniQure in the third quarter valued at $117,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. Barclays reduced their price target on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Monday, March 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Cantor Fitzgerald restated a “neutral” rating and set a $9.00 target price (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Finally, Wolfe Research assumed coverage on shares of uniQure in a research note on Monday, February 23rd. They set a “peer perform” rating on the stock. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.83.

Insider Buying and Selling at uniQure

In other uniQure news, insider Jeannette Potts sold 3,412 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $30,912.72. Following the transaction, the insider directly owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. This trade represents a 2.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Christian Klemt sold 12,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $108,720.00. Following the transaction, the chief financial officer directly owned 226,581 shares in the company, valued at $2,052,823.86. This represents a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 94,396 shares of company stock worth $1,850,434 in the last quarter. 4.79% of the stock is currently owned by company insiders.

uniQure Trading Down 4.9%

QURE opened at $27.75 on Friday. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The business’s 50 day moving average is $17.95 and its two-hundred day moving average is $23.57. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -7.97 and a beta of 0.87.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. On average, research analysts predict that uniQure N.V. will post -3.68 EPS for the current year.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.